<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d125">
    <sentence id="DDI-MedLine.d125.s0" text="The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.&#xd;&#xa;">
        <entity id="DDI-MedLine.d125.s0.e0" charOffset="42-48"
            type="drug_n" text="gliftor"/>
        <entity id="DDI-MedLine.d125.s0.e1" charOffset="69-87"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s0.e2" charOffset="92-116"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s0.p0" e1="DDI-MedLine.d125.s0.e0"
            e2="DDI-MedLine.d125.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s0.p1" e1="DDI-MedLine.d125.s0.e0"
            e2="DDI-MedLine.d125.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s0.p2" e1="DDI-MedLine.d125.s0.e1"
            e2="DDI-MedLine.d125.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s1" text="The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. ">
        <entity id="DDI-MedLine.d125.s1.e0" charOffset="30-48"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s1.e1" charOffset="111-117"
            type="drug_n" text="Gliftor"/>
        <entity id="DDI-MedLine.d125.s1.e2" charOffset="120-142"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s1.p0" e1="DDI-MedLine.d125.s1.e0"
            e2="DDI-MedLine.d125.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s1.p1" e1="DDI-MedLine.d125.s1.e0"
            e2="DDI-MedLine.d125.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s1.p2" e1="DDI-MedLine.d125.s1.e1"
            e2="DDI-MedLine.d125.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s2" text="Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. ">
        <entity id="DDI-MedLine.d125.s2.e0" charOffset="91-109"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s2.e1" charOffset="114-138"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s2.p0" e1="DDI-MedLine.d125.s2.e0"
            e2="DDI-MedLine.d125.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s3" text="Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. ">
        <entity id="DDI-MedLine.d125.s3.e0" charOffset="18-36"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s3.e1" charOffset="94-118"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s3.p0" e1="DDI-MedLine.d125.s3.e0"
            e2="DDI-MedLine.d125.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s4" text="Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. ">
        <entity id="DDI-MedLine.d125.s4.e0" charOffset="19-37"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s4.e1" charOffset="88-112"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s4.e2" charOffset="201-223"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s4.p0" e1="DDI-MedLine.d125.s4.e0"
            e2="DDI-MedLine.d125.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s4.p1" e1="DDI-MedLine.d125.s4.e0"
            e2="DDI-MedLine.d125.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s4.p2" e1="DDI-MedLine.d125.s4.e1"
            e2="DDI-MedLine.d125.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s5" text="We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ">
        <entity id="DDI-MedLine.d125.s5.e0" charOffset="38-60"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s5.e1" charOffset="65-83"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s5.e2" charOffset="181-205"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s5.e3" charOffset="212-234"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s5.p0" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p1" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p2" e1="DDI-MedLine.d125.s5.e0"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p3" e1="DDI-MedLine.d125.s5.e1"
            e2="DDI-MedLine.d125.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p4" e1="DDI-MedLine.d125.s5.e1"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s5.p5" e1="DDI-MedLine.d125.s5.e2"
            e2="DDI-MedLine.d125.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s6" text="Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ">
        <entity id="DDI-MedLine.d125.s6.e0" charOffset="24-39"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s6.e1" charOffset="107-129"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s6.e2" charOffset="162-186"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <entity id="DDI-MedLine.d125.s6.e3" charOffset="257-279"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <pair id="DDI-MedLine.d125.s6.p0" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d125.s6.p1" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p2" e1="DDI-MedLine.d125.s6.e0"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p3" e1="DDI-MedLine.d125.s6.e1"
            e2="DDI-MedLine.d125.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p4" e1="DDI-MedLine.d125.s6.e1"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s6.p5" e1="DDI-MedLine.d125.s6.e2"
            e2="DDI-MedLine.d125.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s7" text="However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. ">
        <entity id="DDI-MedLine.d125.s7.e0" charOffset="27-42"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s7.e1" charOffset="96-114"
            type="drug_n" text="1,3-difluoroacetone"/>
        <entity id="DDI-MedLine.d125.s7.e2" charOffset="174-198"
            type="drug_n" text="(-)-erythro-fluorocitrate"/>
        <pair id="DDI-MedLine.d125.s7.p0" e1="DDI-MedLine.d125.s7.e0"
            e2="DDI-MedLine.d125.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d125.s7.p1" e1="DDI-MedLine.d125.s7.e0"
            e2="DDI-MedLine.d125.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s7.p2" e1="DDI-MedLine.d125.s7.e1"
            e2="DDI-MedLine.d125.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d125.s8" text="We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.">
        <entity id="DDI-MedLine.d125.s8.e0" charOffset="62-77"
            type="drug" text="4-methylpyrazole"/>
        <entity id="DDI-MedLine.d125.s8.e1" charOffset="108-130"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s8.e2" charOffset="224-246"
            type="drug_n" text="1,3-difluoro-2-propanol"/>
        <entity id="DDI-MedLine.d125.s8.e3" charOffset="251-269"
            type="drug_n" text="1,3-difluoroacetone"/>
        <pair id="DDI-MedLine.d125.s8.p0" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d125.s8.p1" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p2" e1="DDI-MedLine.d125.s8.e0"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p3" e1="DDI-MedLine.d125.s8.e1"
            e2="DDI-MedLine.d125.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p4" e1="DDI-MedLine.d125.s8.e1"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d125.s8.p5" e1="DDI-MedLine.d125.s8.e2"
            e2="DDI-MedLine.d125.s8.e3" ddi="false"/>
    </sentence>
</document>
